- Home
- SLNHP vs INM Comparison
SLNHP vs INM Comparison
Compare SLNHP & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNHP
- INM
- Stock Information
- Founded
- SLNHP N/A
- INM 1981
- Country
- SLNHP United States
- INM Canada
- Employees
- SLNHP 47
- INM N/A
- Industry
- SLNHP EDP Services
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- SLNHP Technology
- INM Health Care
- Exchange
- SLNHP Nasdaq
- INM Nasdaq
- Market Cap
- SLNHP N/A
- INM 3.2M
- IPO Year
- SLNHP N/A
- INM N/A
- Fundamental
- Price
- SLNHP $4.00
- INM $3.05
- Analyst Decision
- SLNHP
- INM
- Analyst Count
- SLNHP 0
- INM 0
- Target Price
- SLNHP N/A
- INM N/A
- AVG Volume (30 Days)
- SLNHP N/A
- INM 5.8M
- Earning Date
- SLNHP N/A
- INM 05-12-2025
- Dividend Yield
- SLNHP N/A
- INM N/A
- EPS Growth
- SLNHP N/A
- INM N/A
- EPS
- SLNHP N/A
- INM N/A
- Revenue
- SLNHP N/A
- INM $4,920,990.00
- Revenue This Year
- SLNHP N/A
- INM N/A
- Revenue Next Year
- SLNHP N/A
- INM N/A
- P/E Ratio
- SLNHP N/A
- INM N/A
- Revenue Growth
- SLNHP N/A
- INM N/A
- 52 Week Low
- SLNHP N/A
- INM $1.72
- 52 Week High
- SLNHP N/A
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- SLNHP 63.63
- INM 51.64
- Support Level
- SLNHP $1.95
- INM $3.32
- Resistance Level
- SLNHP $2.47
- INM $5.50
- Average True Range (ATR)
- SLNHP 0.39
- INM 0.37
- MACD
- SLNHP 0.19
- INM 0.04
- Stochastic Oscillator
- SLNHP 100.00
- INM 24.38
About SLNHP Soluna Holdings Inc 9.0% Series A Cumulative Perpetual Preferred Stock
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.